



AALBORG UNIVERSITY
DENMARK

Aalborg Universitet

Quality of life in individuals with patellofemoral pain

A systematic review including meta-analysis

Coburn, Sally L; Barton, Christian J; Filbay, Stephanie R; Hart, Harvi F; Rathleff, Michael S; Crossley, Kay M

Published in:
Physical Therapy in Sport

DOI (link to publication from Publisher):
[10.1016/j.ptsp.2018.06.006](https://doi.org/10.1016/j.ptsp.2018.06.006)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2018

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Coburn, S. L., Barton, C. J., Filbay, S. R., Hart, H. F., Rathleff, M. S., & Crossley, K. M. (2018). Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis. *Physical Therapy in Sport*, 33, 96-108. <https://doi.org/10.1016/j.ptsp.2018.06.006>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -


Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis

Sally L. Coburn, Christian J. Barton, Stephanie R. Filbay, Harvi F. Hart, Michael S. Rathleff, Kay M. Crossley



PII: S1466-853X(18)30192-5

DOI: [10.1016/j.ptsp.2018.06.006](https://doi.org/10.1016/j.ptsp.2018.06.006)

Reference: YPTSP 918

To appear in: *Physical Therapy in Sport*

Received Date: 10 May 2018

Accepted Date: 22 June 2018

Please cite this article as: Coburn, S.L., Barton, C.J., Filbay, S.R., Hart, H.F., Rathleff, M.S., Crossley, K.M., Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis, *Physical Therapy in Sports* (2018), doi: 10.1016/j.ptsp.2018.06.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

TITLE PAGE**Quality of Life in Individuals with Patellofemoral Pain: A Systematic Review Including Meta-analysis.**

Sally L. Coburn, PT, MSc¹, Christian J. Barton, PT, PhD¹, Stephanie R. Filbay, PT, PhD², Harvi F. Hart, PhD¹, Michael S. Rathleff, MD, PhD^{3,4}, Kay M. Crossley, PT PhD¹.

¹La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, La Trobe University, Bundoora, Victoria, Australia.

²Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Science, Botnar Research Centre, University of Oxford, Oxford, England.

³Research Unit for General Practice in Aalborg, Department of Clinical Medicine, Aalborg University, Denmark.

⁴Department of Occupational therapy and Physiotherapy, Aalborg University Hospital, Denmark.

PROSPERO registration number: CRD42016026307

WORD COUNT: abstract: 200 words; manuscript: 4012 words (excluding key words, highlights, figures, tables and references)

ADDRESS FOR CORRESPONDENCE

Kay M Crossley

La Trobe Sport and Exercise Medicine Research Centre

School of Allied Health, College of Science, Health and Engineering

La Trobe University, Bundoora Vic. 3086 Australia

Tel: +61 3 9479 3902

Fax: +61 3 9479 5768

E-mail: k.crossley@latrobe.edu.au

1 **ANONYMOUS TITLE PAGE**

2

3 **Quality of Life in Individuals with Patellofemoral Pain: A Systematic Review Including**

4 **Meta-analysis.**

5

6

7

ACCEPTED MANUSCRIPT

8 ABSTRACT

9 **Objective:** The aim of this systematic review is to describe QoL in individuals with PFP, and
10 determine the impact of PFP interventions on QoL.

11 **Methods:** Five databases were searched for studies reporting QoL in individuals with PFP,
12 with mean age under 50 years. Data were pooled based on QoL tool (e.g. Knee Injury and
13 Osteoarthritis Outcome Score [KOOS] QoL subscale, Short-Form 36 item health survey [SF-
14 36]) using random-effects models, or through narrative synthesis where inadequate data were
15 available.

16 **Results:** Individuals with PFP, had worse KOOS-QOL scores (pooled mean: 47[95% CI: 34
17 to 61] and health-related QoL (pooled SF-36 PCS and MCS: 47[95% CI: 41 to 53] and
18 54[95% CI: 47 to 62], respectively) compared with pain-free controls and population norms.
19 Physical interventions were associated with improvements in knee- and health- related QoL
20 in individuals with PFP in repeated measures studies. However, the effect of physical
21 interventions compared to a control treatment was conflicting.

22 **Conclusion:** Individuals with PFP aged under 50 years, have markedly reduced knee- and
23 health-related QoL compared to pain-free controls and population norms. Knee- and health-
24 related QoL may improve following intervention, but it is unclear if these improvements are
25 greater than that which occur in a control group.

26 **Keywords:** anterior knee pain, patellofemoral pain syndrome, KOOS, SF-36, intervention
27

28 1. INTRODUCTION

29 Patellofemoral pain (PFP) is a common disorder of the knee,⁵⁵ prevalent in adolescent³¹ and
30 adult populations,⁶² and particularly prevalent in physically active individuals.³⁵ PFP is a
31 chronic, painful condition predominantly of insidious onset, which often persists despite
32 provision of evidence-based treatments.³⁷ Research suggests that 57% of individuals with

33 PFP may experience persistent symptoms and unfavourable outcomes 5-8 years after
34 enrolment in a clinical trial.²⁸ Moreover, symptom severity may remain unchanged or
35 progress in 50% of affected individuals,⁷ often restricting an individual's participation in
36 physical activity⁴⁰ and potentially reducing quality of life (QoL).

37

38 Health-related QoL is a multi-dimensional concept, encompassing physical, psychological
39 and social aspects associated with a disease or its treatment.¹⁹ Disease-specific and generic
40 health-related QoL measures are used to evaluate patient experience of a musculoskeletal
41 condition and the benefit of therapeutic interventions.⁴⁶ The patients' perspective and
42 experience should be paramount when evaluating the impact of a condition or the efficacy of
43 an intervention.⁴⁵ The use of QoL instruments recognizes that patient perceptions do not
44 always match with knee pathology⁵⁰ or findings from a clinical examination of the knee.²⁴
45 Although rarely the primary outcome of interest, knee- and health- related QoL outcomes
46 have been reported in a number of studies investigating individuals with PFP, and have been
47 used to evaluate intervention efficacy for this condition. Synthesis of this evidence will
48 provide a better understanding of the impact of PFP and the influence of specific treatment
49 strategies on QoL.

50

51 This systematic review aims to: (i) describe QoL in individuals with PFP compared to pain-
52 free controls and population norms; (2) evaluate whether intervention is associated with
53 improved QoL in individuals with PFP; and (3) identify factors associated with QoL in
54 individuals with PFP.

55

56 **2. METHODS**

57 This systematic review followed the Preferred Reporting Items for Systematic reviews and
58 Meta-Analysis (PRISMA) guidelines,³⁰ with the protocol prospectively registered on
59 PROSPERO (<http://www.crd.york.ac.uk/PROSPERO/>; CRD 42016026307, 12 April 2016).

60 There were no peer-reviewed literature reviews of this topic at the time.

61

62 **2.1 Literature Search Strategy**

63 A comprehensive search strategy was devised for the following electronic databases: (i)
64 AMED, (ii) CINAHL via EBSCO, (iii) Cochrane Central Register of Controlled Trials, (iv)
65 EMBASE via OVID, and (v) MEDLINE via OVID. Diagnostic search terms from a
66 Cochrane systematic review of exercise interventions for individuals with PFP were used to
67 identify PFP literature;⁵⁴ and combined with terms for QoL measurement tools, similar to the
68 strategy used by Filbay et al, 2014.¹⁷ The search strategy for MEDLINE is presented in
69 Appendix 1, and was adjusted to suit other databases. All potentially eligible papers were
70 imported into EndNote X7.2.1 (Thomson Reuters, Carlsbad, California, USA) and duplicates
71 were removed. The search was conducted in April, 2016. Two reviewers (X and Y)
72 independently screened the titles and abstracts of all articles using a checklist based on the
73 eligibility criteria. Papers with insufficient information in title and abstract to determine
74 eligibility were retained for full-text evaluation using the same checklist. Reference lists of all
75 publications considered for inclusion were hand-searched and citation tracking was
76 completed using Google Scholar. The final lists of eligible articles were compared between
77 the two reviewers, with a third reviewer available to resolve any disagreement (Z).

78

79 **2.2 Selection Criteria**

80 All studies reporting QoL in individuals with PFP were included, regardless of study design
81 methodology. Participants in the studies were required to be experiencing PFP/retropatellar

82 knee pain/anterior knee pain or be diagnosed with chondromalacia patella. Studies were
83 excluded if participants had other knee conditions (such as a ligament or meniscal injury,
84 patellar tendinopathy, recurrent patella subluxation, diagnosed radiographic osteoarthritis or
85 were preoperative patients awaiting surgery for their PFP). No other treatment intervention
86 was excluded. To reduce the likelihood that a proportion of study participants may have
87 undiagnosed patellofemoral osteoarthritis (PFOA) studies of participants with mean age of
88 greater than 50 years were excluded from this systematic review.²¹ Studies not published in
89 English, French, German or Danish were ineligible. In the case of multiple studies using the
90 same cohort, the study reporting QoL outcomes for the largest sample size was included.

91

92 **2.3 Assessment of Reported Methodological Quality**

93 Two independent reviewers (X, W) rated the reported methodological quality of included
94 studies using two separate scales. The first scale was a checklist adapted from the 21-item
95 Downs and Black checklist which is suitable for randomised and non-randomised studies
96 (Appendix 2)¹⁵. Items were scored according to the method used by Downs and Black (1998):
97 'Yes' (score=1), 'No' (score=0), or 'Not Applicable' (items removed from scoring), except
98 for Item 5 (i.e. description of principle confounders clearly described) which was scored
99 'Yes' (score=2), 'Partially' (score=1) or 'No' (score=0). Items considered not applicable to
100 assess intervention studies were removed, resulting in a modified checklist of 15 items. One
101 of the 15 items, concerning follow-up, was not applicable to cross-sectional studies and 6
102 items were not applicable to validity and reliability studies so were removed from scoring,
103 leaving 14 and 8 items, respectively. Therefore a percentage score was calculated from
104 relevant items for the three different study designs. The median value was identified to assign
105 a level of methodological quality. Studies were classified as higher reported quality (study

106 score equal to or greater than the median value) and lower reported quality (study score less
107 than the median value).³⁸

108

109 The second scale used was The Cochrane Risk of Bias Tool.²² This tool is specifically used
110 for controlled intervention studies to provide explicit assessment of each component risk of
111 bias.⁵⁸ The additional quality assessment tool provided more comprehensive evaluation of
112 intervention study outcomes to inform the second aim of this review. The Cochrane Risk of
113 Bias Tool is comprised of a 7 domain checklist to assess selection bias (2 domains),
114 performance bias (1 domain), detection bias (1 domain), attrition bias (1 domain), reporting
115 bias (1 domain), and other bias (1 domain). Domains were recorded as low or high risk of
116 bias or risk of bias unclear. Risk of bias within studies was summarised as low risk (low risk
117 of bias for all domains), unclear risk (low or unclear risk of bias for all domains), or high risk
118 (high risk of bias for one or more domain).²² Any inter-rater disagreement was discussed in a
119 consensus meeting and unresolved items were taken to a third reviewer (Z) for consensus. A
120 level of evidence was assigned for intervention study data using the statistical outcomes and
121 methodological quality of included studies, based on recommendations by van Tulder.⁵⁶

122

123 **2.4 Data Management and Statistical Analyses**

124 Participant (e.g. sex, age, BMI) and study (e.g. study design) characteristics, QoL, and type of
125 treatment for intervention studies, were independently extracted (X). If sufficient data were
126 not reported in the published article or supplementary material provided, the corresponding
127 author was contacted to request further information. Data were cross-checked by a second
128 reviewer (V). When intervention studies reported QoL data at multiple time points post-
129 treatment for PFP, data from the first follow-up after treatment were extracted. If BMI data
130 were not reported, then it was estimated from mean height and mass data.

131

132 Normative QoL data were obtained from previously published population studies. Studies
133 with QoL data available from the largest number of participants of a comparable age were
134 selected.^{9,23,29,33} Pain-free control data were obtained from included studies.^{5,36,39,42}

135

136 Data were analyzed based on QoL instrument. Knee-related QoL was measured with the
137 Knee injury and Osteoarthritis Outcome Score QoL subscale (KOOS-QoL). Health-related
138 QoL was measured with: i) the 36-Item Short Form Survey (SF-36) reported as 8 domain
139 scores and/or physical and mental component summary scores (PCS and MCS respectively),
140 (ii) the 8-Item Short Form Survey (SF-8) reported as 8 domain scores, or (iii) the European
141 QoL-5 Dimension (EQ-5D) index score. To address the first aim of this review, pooled mean
142 [95% CI] QoL data from individuals with PFP, pain-free controls, and normative populations
143 are presented. Baseline mean QoL scores from intervention studies were pooled with QoL
144 data from all other studies. To address the second aim of this review, random effects meta-
145 analyses were used to compare QoL between pre- and post-treatment for repeated measure
146 design intervention studies and to compare QoL outcomes between treatment and control
147 groups for controlled intervention studies (Review Manager Version 5.3). Pooled findings of
148 intervention studies were considered heterogeneous if $I^2 > 50\%$ was statistically significant
149 ($p < 0.05$). Standardized mean differences (SMD) [95% CI] are reported. The magnitude of the
150 pooled SMD was interpreted based on Cohen's criteria, where $SMD \geq 0.8$ was interpreted as a
151 large effect, >0.5 and <0.8 a moderate effect, and >0.2 and <0.5 a small effect.¹⁸

152

153 **2.5 Deviations from study protocol**

154 Initially, we were interested in exploring the association between secondary outcomes (i.e.
155 body mass index [BMI], age, pain) and QoL through a meta-regression analysis (ie. Aim 3).

156 However, due to a low number of included case-control studies for each QoL instrument, a
157 meta-analysis comparing QoL and secondary outcomes was not possible. Considering at least
158 10 studies should be included in a meta-analysis for each covariate in order for a meta-
159 regression analysis to be meaningful, it was not possible to conduct the planned meta-
160 regression analysis⁸. Additionally, the Cochrane risk of bias tool²² was added to enhance
161 examination of the risk of bias of included randomized controlled trials (RCT).

162

163 **3.0 RESULTS**

164 **3.1 Search Strategy, Methodological Quality, and Risk of Bias**

165 The comprehensive search strategy identified 1573 titles, with 1304 titles and abstracts
166 evaluated after removal of duplicates. The full-text of 93 articles were retrieved and assessed
167 for eligibility. Two additional papers were identified by citation tracking, and four were
168 identified in an updated search performed prior to final data analysis using the same search
169 strategy, in January, 2017. Twenty-one studies met the selection criteria (Figure 1).




FIGURE 1: Flow chart of the study selection process.

170

171 Thirteen authors (for 15 studies) were contacted to obtain raw data, 10 responded and of
 172 these, 8 supplied data for 9 studies^{4,11,14,32,34,36,41,47,57}. QoL data were extracted for 1111
 173 individuals with PFP and 100 pain-free controls. Characteristics of included studies are
 174 presented in Table 1.

175

176

177

178

179

180

181 **TABLE 1:** *Characteristics of the included studies.*

Study	PFP participants	Control participants	Aim/Comparison/ Intervention	Rx Duration	QOL measure(s)	Domain	PFP	Comparator
Cross-sectional								
Assa 2015 (Israel)	n = 157 Age = 30 (5) BMI = 24 (3) W = 42%	n = 31, Pain-free Age = 32 (4) BMI = 23 (3) W = 45%	PFP compared to control		SF-36	PF RP BP GH V SF RE MH PCS MCS	65 [62 to 68] 40 [34 to 45] 50 [47 to 54] 65 [62 to 68] 54 [51 to 57] 77 [73 to 80] 65 [58 to 71] 69 [67 to 72] 55 [52 to 57] 66 [63 to 69]	97 [96 to 99] 97 [93 to 101] 92 [88 to 96] 82 [88 to 96] 72 [67 to 75] 97 [95 to 100] 98 [95 to 101] 79 [76 to 83] 88 [86 to 90] 86 [83 to 88]
Rathleff CR 2013 (Denmark)	n = 20 Age = 15 (1) BMI = 20 (3) W = 80%	n = 20, Healthy Age = 15 (1) BMI = 19 (1) W = 80%	PFP compared to control		KOOS-QOL EQ-5D (index)		54 [49 to 60] 0.72 [0.68 to 0.78]	98 [95 to 101] 1.0 [1.0 to 1.0]
Rathleff MS 2013 (Denmark)	n = 57 ^Δ Age = 17 (1) BMI = 21 (2) W = 100%	n = 29, Pain-free Age = 17 (1) BMI = 21 (3) W = 100%	PFP compared to control		KOOS-QOL		54 [†] [50 to 58]	99 [98 to 100]
Rathleff MS 2016 (Denmark)	n = 20 ^Δ Age = 20 (20-21) BMI = 22* (NR) W = 100%	n = 20, Pain-free Age = 21 (19-21) BMI = 22* (NR) W = 100%	PFP compared to control		KOOS-QOL		55 [†] [47 to 63]	97 [94 to 100]
Study	PFP	Control	Aim/Comparison/ Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
Choeung 2013	<i>Amateur athletes</i>		Amateur compared to		SF-36	PF	88 [80 to 96]	

(China)	n = 19 Age = 23 (1) BMI = 20* (NR) W = NR	professional athletes with PFP		RP	78 [59 to 96]
	BP			63 [54 to 72]	
				GH	66 [56 to 74]
				V	63 [55 to 72]
				SF	83 [72 to 93]
				RE	67 [45 to 88]
				MH	74 [66 to 81]
	<i>Professional athletes</i>			PF	75 [67 to 82]
	n = 19			RP	42 [23 to 61]
	Age = 21 (2)			BP	51 [54 to 72]
	BMI = 20* (NR)			GH	65 [56 to 74]
	W = NR			V	55 [44 to 65]
				SF	78 [71 to 86]
				RE	58 [37 to 79]
				MH	65 [58 to 71]
Silva 2016 (Brazil)	<i>Non-athletes</i> n = 34 Age = 15 (1) BMI = 22* (NR) W = 32%	Non-athletes compared to athletes with with PFP		KOOS-QOL	68 [62 to 74]
	<i>Athletes</i> n = 22 Age = 14 (1) BMI = 22 () W = 36%				78 [70 to 86]
Vincent 2010 (Australia)	n=33 Age = NR BMI = NR W = NR	Knee pain (PFP subgroup obtained from author)		SF-8	PF 49 [46 to 52] RP 39 [36 to 42] BP 35 [30 to 39] GH 43 [41 to 46] V 51 [48 to 53] SF 46 [43 to 49]

Study	PFP	Control	Aim/Comparison/ Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
Vincent 2010 (Australia) (Continued)	n=33 Age = NR BMI = NR W = NR		Knee pain (PFP subgroup obtained from author)		SF-8	MH PCS MCS	51 [49 to 54] 48 [46 to 51] 40 [36 to 44] 54 [51 to 57]	
Validity and reliability								
Apivotgaroon 2016 (Thailand)	n = 49 Age = 47 (11) BMI = 25 (5) W = 80%		Testing validity & reliability of Kujala in PFP		SF-36	PF RP BP GH V SF RE MH PCS MCS	33 [26 to 39] 54 [48 to 60] 42 [37 to 47] 47 [41 to 54] 52 [47 to 57] 54 [49 to 59] 55 [49 to 62] 59 [53 to 64] 46 [41 to 50] 53 [49 to 58]	
Cheung 2012 (China)	n = 64 Age = 30 (6) BMI = 22* (NR) W = 41%		Testing validity & reliability Kujala in PFP		SF-36	PF RP BP GH V SF RE MH	88 [85 to 91] 76 [68 to 84] 58 [52 to 63] 64 [60 to 69] 62 [58 to 66] 84 [79 to 89] 79 [70 to 88] 73 [69 to 76]	
Negahban 2013 (Iran)	n = 100 Age = 25 (7) BMI = 23* (NR) W = 71%		Validity & reliability of Functional Index Questionnaire & Modified Functional Index Questionnaire in individuals with PFP		SF-36	PF RP BP GH V SF RE	65 [60 to 70] 48 [40 to 55] 51 [47 to 55] 54 [50 to 57] 58 [56 to 61] 66 [62 to 70] 45 [36 to 54]	

Study	PFP	Control	Comparison or Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
						MH	64 [61 to 67]	
						PCS	55 [52 to 58]	
						MCS	58 [54 to 61]	
Controlled intervention studies								
Crossley 2002 (Australia)	<i>Treatment</i> n = 36 Age = 29 (8) BMI = 24 (4) W = 64%		Randomized controlled trial comparing change in QOL after active MMP in PFP vs. change after placebo intervention in PFP	6 weeks	SF-36	PF	64 [57 to 71]	79 [73 to 85]
						RP	59 [47 to 72]	80 [70 to 91]
						BP	52 [45 to 59]	77 [71 to 83]
						GH	71 [64 to 76]	78 [72 to 84]
						V	55 [49 to 61]	64 [58 to 70]
						SF	67 [60 to 74]	75 [69 to 81]
						RE	81 [69 to 93]	85 [75 to 95]
						MH	72 [67 to 77]	82 [78 to 86]
						PF	64 [58 to 70]	82 [78 to 86]
						RP	57 [40 to 68]	79 [68 to 90]
						BP	52 [44 to 58]	72 [65 to 79]
						GH	71 [64 to 78]	77 [72 to 83]
						V	56 [51 to 63]	63 [57 to 69]
						SF	69 [63 to 76]	80 [73 to 87]
RE	73 [60 to 86]	89 [82 to 96]						
MH	75 [70 to 81]	81 [77 to 85]						
		<i>Placebo</i> N = 34 Age = 26 (8) BMI = 25 (4) W = 66%		6 weeks				
Petersen 2016 (Germany)	<i>MMP & brace</i> n = 78 Age = 28 (9) BMI = 23 (2) W = 51%		Randomized trial comparing change in QOL following MMP & brace intervention vs. MMP alone	6 weeks	KOOS-QOL		40 [37 to 44]	69 [65 to 72]
	<i>MMP</i> n = 78 Age = 28 (8)			6 weeks			43 [40 to 45]	60 [55 to 65]

BMI = 23 (1)

W = 61%

Study	PFP	Control	Comparison or Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
Rathleff MS 2014 (Denmark)	<i>Physiotherapy + Education</i> n = 62 Age = 17 (1) BMI = 21 (3) W = 74%		Cluster randomized trial comparing change in QOL following supervised physiotherapy + education vs. education alone	12 weeks	KOOS-QOL		57 [52 to 61]	62 [54 to 71]
	<i>Education</i> n = 59 Age = 17 (1) BMI = 22 (3) W = 86%			12 weeks			53 [49 to 57]	54 [52 to 57]
Syme 2011 (UK)	<i>VMO training</i> n = 23 Age = 29 (8) BMI = 26 (1) W = 57%		Randomized controlled trial comparing change in QOL following vastus medialis oblique selective training vs. general quadriceps strengthening	8 weeks	SF-36	PCS	45 [42 to 48]	53 [49 to 58]
						MCS	45 [42 to 48]	46 [42 to 51]
	<i>Quadriceps strengthening</i> n = 23 Age = 27 (8) BMI = 26 (1) W = 57%			8 weeks		PCS	47 [43 to 50]	54 [49 to 60]
						MCS	47 [43 to 50]	50 [47 to 54]
		<i>No treatment</i> n = 23		8 weeks		PCS	47 [43 to 50]	40 [32 to 48]
						MCS	47 [43 to 50]	49 [44 to 54]

Age = 29 (6)
 BMI = 26 (1)
 W = 65%

Study	PFP	Control	Comparison or Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
<i>Repeated measure intervention studies</i>								
Akkurt 2010 (Turkey)	n = 22 Age = 35 (8) BMI = NR W = 100%		Repeated measures study of QOL following isokinetic exercise	6 weeks	SF-36	PCS MCS	40 [31 to 49] 51 [41 to 60]	63 [55 to 72] 67 [59 to 75]
Banan 2016 (Iran)	n = 25 Age = 35 (10) BMI = 25 (7) W = 80%		Repeated measures study of QOL following rigid taping	4 weeks	KOOS-QOL		12 [8 to 15]	13 [9 to 17]
Eapen 2011 (India)	n = 20 Age = 28 (7) BMI = NR W = 60%		Repeated measures study of QOL following eccentric exercise	2 weeks	SF-36	BP PCS MCS	45 [40 to 51] 37 [35 to 39] 42 [39 to 45]	75 [69 to 80] 48 [46 to 49] 44 [43 to 46]
Haim 2013 (Israel)	n = 48 Age = 31 (7) BMI = 24 W = 44%		Repeated measures study of QOL following use of biomechanical device in shoe	26 weeks	SF-36	PF RP BP GH V SF RE MH PCS MCS	61 [55 to 66] 42 [30 to 53] 51 [44 to 57] 60 [55 to 66] 50 [44 to 56] 76 [69 to 83] 69 [57 to 82] 68 [64 to 73] 53 [47 to 58] 65 [59 to 71]	64 [58 to 70] 54 [43 to 65] 58 [53 to 64] 65 [59 to 70] 54 [48 to 59] 81 [74 to 88] 73 [61 to 85] 68 [63 to 73] 59 [54 to 64] 68 [63 to 73]
Kuru 2012 (Turkey)	<i>Kinesio tape & exercise</i> n = 15 Age = 33 (12) BMI = 24 (5)		Repeated measures study of QOL following Kinesio tape & exercise vs. Electrical stimulation	6 weeks	SF-36	PF RP BP GH V	41 [37 to 45] 34 [29 to 39] 40 [36 to 44] 40 [36 to 45] 46 [42 to 49]	49 [45 to 52] 45 [41 to 50] 50 [47 to 53] 44 [40 to 48] 51 [47 to 54]

Study	PFP	Control	Comparison or Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
	W = 80%		+exercise			SF	42 [38 to 47]	47 [44 to 50]
						RE	39 [32 to 47]	50 [46 to 55]
						MH	40 [35 to 45]	44 [41 to 47]
Kuru 2012 (Turkey) (Continued)	Electrical stimulation & exercise n = 15 Age = 41 (11) BMI = 27 (4) W = 93%			6 weeks	SF-36	PF	39 [33 to 45]	48 [43 to 53]
						RP	43 [35 to 50]	53 [49 to 57]
						BP	43 [38 to 49]	52 [49 to 54]
						GH	43 [37 to 49]	46 [41 to 51]
						V	44 [38 to 49]	48 [42 to 53]
						SF	44 [39 to 49]	49 [44 to 54]
						RE	43 [34 to 51]	53 [48 to 57]
						MH	40 [33 to 46]	46 [41 to 50]
Sinclair 2016 (UK)	n = 20 Age = NR BMI = NR W = 45%		Repeated measures study of QOL following brace use	2 weeks	KOOS-QOL		53 [47 to 58]	68 [60 to 76]
Tsai 2015 (USA)	n = 12 Age = 39 (NR) BMI = 23 (NR) W = 75%		Repeated measures study of QOL following off-axis elliptical training	6 weeks	KOOS-QOL		49 [36 to 62]	61 [48 to 74]

Note. Demographic data are presented as mean (standard deviation), unless otherwise stated. Quality of life data are presented as mean [95% confidence interval].

Abbreviations as follows: PFP, patellofemoral pain; Rx, treatment; QOL, quality of life; BMI, body mass index (kg/m²); W, women; NR, not reported; KOOS, Knee Injury and Osteoarthritis Outcome Score; SF-36, Short-Form 36-Item Health Survey; PF, physical function; RP, role physical; BP, bodily pain; GH, general health; V, vitality; SF-social function; RE, role emotional; MH, mental health; SF-8, Short-Form 8-Item Health Survey; MMP, multi-modal physiotherapy; * symbol denotes BMI not reported but estimated from height and mass; † is PFP participant data derived from participants included in largest cohort reported in 2014 paper

182

183

184 Eleven studies investigated the effect of a treatment intervention on QoL in PFP individuals.
185 Interventions included single treatment and multi-modal physical therapy, shoe inserts, braces
186 and elliptical training. The methodological quality scores ranged from 31-100%, with a
187 median score of 67% (Table 2). There were 12 studies of higher quality and nine studies of
188 lower quality. Of the four controlled intervention studies, there was one low risk of bias
189 study, one unclear, and two high risk of bias studies (Table 3).

190

191 **TABLE 2.** *Reported methodological quality of the included studies.*

Author	1	2	3	5	6	7	10	11	12	15	18	20	25	26	27	Score	Total	%	Quality
<i>QOL in PFP (cross-section studies compared to control)</i>																			
Assa 2013	1	1	1	1	1	1	1	0	0	1	1	1	0	N/A	1	11	15	73	Higher
Rathleff CR 2013	1	1	1	2	1	1	1	1	0	1	1	1	1	N/A	0	13	15	87	Higher
Rathleff MS 2013	1	1	1	2	1	0	1	1	0	0	1	0	1	N/A	0	10	15	67	Higher
Rathleff MS 2016	1	1	1	2	1	1	1	1	0	1	1	1	1	N/A	1	14	15	93	Higher
<i>QOL in PFP (cross-section & validity studies)</i>																			
Apivatgaroon 2016	1	1	1	N/A	1	1	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	6	8	75	Higher
Cheung 2012	1	1	1	N/A	1	0	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	5	8	63	Lower
Cheung 2013	1	1	1	2	1	1	1	0	0	0	0	1	1	N/A	1	11	15	73	Higher
Negahban 2013	1	1	1	N/A	1	1	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	6	8	75	Higher
Silva 2016	1	1	1	2	1	1	1	1	0	0	1	1	1	N/A	1	13	15	87	Higher
Vincent 2010	1	1	0	2	1	0	1	0	0	0	1	1	1	N/A	1	10	15	67	Higher
<i>Effect of intervention on QOL for PFP (randomised controlled studies)</i>																			
Crossley 2002	1	1	1	2	1	1	1	1	0	1	1	1	1	1	1	15	16	94	Higher
Petersen 2016	1	1	1	1	1	0	0	1	0	0	1	1	1	0	1	10	16	63	Lower
Rathleff 2014	1	1	1	2	1	1	0	1	1	1	1	1	1	1	1	15	16	94	Higher
Syme 2009	1	1	1	2	1	1	0	1	1	1	1	1	1	1	1	15	16	94	Higher
<i>Effect of intervention on QOL for PFP (repeated measures studies)</i>																			
Akkurt 2010	1	1	1	0	1	1	1	0	0	0	0	0	0	0	0	6	16	38	Lower
Banan 2016	1	1	1	1	1	1	1	0	0	0	0	1	0	0	0	8	16	50	Lower
Eapen 2011	1	1	1	0	1	1	1	0	0	0	1	0	0	0	1	8	16	50	Lower
Haim 2013	1	1	1	1	1	1	1	0	0	0	1	0	0	N/A	1	9	15	60	Lower
Kuru 2012	1	1	1	1	1	1	1	0	0	0	0	0	0	1	0	8	16	50	Lower
Sinclair 2016	1	1	0	0	1	1	0	0	0	0	1	0	0	0	0	5	16	31	Lower
Tsai 2015	1	1	0	0	1	1	0	0	0	0	1	0	0	1	1	7	16	44	Lower

192 *Note. N/A is not applicable. Higher quality is median score (67%) or above and lower quality is below median (<67%)*

193

194 **TABLE 3:** *Risk of bias of included controlled intervention studies.*

Study	Random sequence generation	Allocation concealment	Blinding of participants & personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias	Risk of bias within trial
Crossley 2002	Low	Low	Low	Low	Low	Low	Low	Low risk
Petersen 2016	High	High	High	High	Unclear	Unclear	High	High risk
Rathleff 2014	Low	Low	Unclear	Low	Low	Low	Low	Unclear risk
Syme 2009	Low	Low	High	Low	Low	Low	High	High risk

195

196 *Low risk of bias (bias if present is unlikely to alter the results seriously);*197 *Unclear risk of bias (a risk of bias that raises some doubt about the results);*198 *High risk of bias (bias may alter the results seriously)*

199

200

201

202

203

204

205

206

207

208


209

210 3.3 QoL in Individuals with PFP

211 Knee-related QoL in individuals with PFP

212 Seven studies reported knee-related QoL (KOOS-QoL) in individuals with PFP.^{6,34,36,41,47,48,51}

213 The pooled mean KOOS-QoL score from 7 studies (3 higher quality and 4 lower quality) in
 214 individuals with PFP was 47 [95% CI: 34 to 61] (Figure 2).



215 **FIGURE 2:** *Knee-related quality of life in individuals with patellofemoral pain.*

216

217 One study considered an outlier (i.e. mean KOOS-QoL score (11) was outside the 95% CI for
 218 the pooled mean),⁶ when excluded from the analysis, resulted in a pooled mean KOOS-QoL

219 score of 53 [95% CI: 45 to 61]. A single study reported knee-related QoL in athletes with
 220 PFP (KOOS-QoL score, 78 [95% CI: 70 to 86]) (Table 4).⁴⁷

221

222

223

224

225

226

227 **TABLE 4.** *Quality of life in athletes with PFP compared to active population norms.*

	Included studies			Active Population Norm	Mean difference	
	PFP-Pooled	Silva 2016 PFP-Athletes		Cameron 2013	PFP Athletes v Active Norm	
KOOS-QoL	47 [34 to 61]	78 [70 to 86]		92 (12)	14	
SF-36	PFP-Pooled	Cheung 2013		Huffman 2008	Mean difference	
		PFP-Amateur athletes	PFP-Professional athletes		PFP Amateur athletes v Active Norm	PFP Professional athletes v Active Norm
PF	59 [45 to 74]	88 [80 to 96]	75 [67 to 82]	99 [98 to 100]	11	24
RP	50 (41 to 60)	78 [59 to 96]	42 [23 to 62]	96 [94 to 98]	18	54
BP	49 [45 to 53]	63 [54 to 72]	51 [41 to 62]	89 [87 to 91]	26	38
GH	57 [50 to 66]	66 [56 to 76]	65 [56 to 74]	86 [85 to 88]	20	21
V	54 [49 to 58]	63 [55 to 72]	55 [44 to 65]	71 [69 to 73]	8	16
SF	67 [55 to 79]	83 [72 to 93]	78 [71 to 86]	96 [95 to 98]	13	18
RE	61 [50 to 73]	67 [45 to 88]	58 [37 to 79]	98 [97 to 99]	31	40
MH	64 [55 to 72]	74 [66 to 80]	65 [58 to 71]	83 [82 to 85]	9	18

228

229 *All data reported as mean, [95%CI].*230 *Active population norm reported in groups with no history of injury*

231

232 *Knee-related QoL in individuals with PFP compared to population norms*

233 The previously reported mean KOOS-QoL score from a general population sample of young
 234 adults was 84 [95% CI: 81 to 88]³³. Based on the pooled scores, individuals with PFP had
 235 worse knee-related QoL relative to this general population sample (mean difference: 37;
 236 [KOOS-QoL 95% CI: 34 to 61]). The previously published mean KOOS-QoL score from
 237 active individuals (with no history of knee injury) was 92 [95% CI: 92 to 93].⁹ Based on this
 238 data, athletes with PFP had worse knee-related QoL relative to norms from an active
 239 population (mean difference: 14; [KOOS-QoL 95% CI: 70 to 86]).

240

241 *Knee-related QoL in individuals with PFP compared to pain-free controls*

242 Three included studies^{36,39,42} provided KOOS-QoL data from three different groups of pain-
243 free individuals (i.e. 69 females) and the pooled mean KOOS-QoL score was 98 [95% CI: 97
244 to 100]. Based on the pooled scores, individuals with PFP had worse knee-related QoL
245 relative to pain-free controls (mean difference: 51).

246

247 Health-related QoL in individuals with PFP

248 Fourteen studies reported health-related QoL in individuals with PFP using SF-36, SF-8, and
249 EQ-5D measures. Eleven studies reported on QoL using the SF-36; eight of these studies
250 reported SF-36 domain scores,^{4,5,11,12,14,20,27,32} seven studies reported SF-36 summary
251 scores^{2,4,5,16,20,32,49} and four reported both domain and summary scores.^{4,5,20,32} One paper used
252 the SF-8⁵⁷ and two studies used the EQ-5D^{36,41} (one study used a youth version (EQ-5D-Y)).³⁶

253

254 Pooled SF-36 domain scores from 7 studies (4 higher quality^{4,5,14,32} and 3 lower quality^{11,20,27})
255 in individuals with PFP were: physical function 59 [95% CI: 45 to 74], role physical 50 [95%
256 CI: 41 to 60], bodily pain 49 [95% CI: 45 to 53], general health 57 [95% CI: 50 to 66],
257 vitality 54 [95% CI: 49 to 58], social function 67 [95% CI: 55 to 79], role emotional 61 [95%
258 CI: 50 to 73] and mental health 64 [95% CI: 55 to 72]. A single study reported health-related
259 QoL (SF-36 domains) in amateur and professional athletes with PFP¹² (Table 4). Pooled SF-
260 36 PCS and MCS scores from 7 studies (4 higher quality^{4,5,32,49} and 3 lower quality^{2,16,20})
261 were 47 [95% CI: 41 to 53] and 54 [95% CI: 47 to 62] respectively.

262

263 A PFP subgroup from a single study⁵⁷ of individuals with knee pain-related diagnoses
264 reported health-related QoL measured with SF-8 (physical function 49 [95% CI: 46 to 52],
265 role physical 39 [95% CI: 36 to 42], bodily pain 35 [95% CI: 30 to 39], general health 43

266 [95% CI: 41 to 46], vitality 51 [95% CI: 48 to 53], social function 46 [95% CI: 43 to 49], role
267 emotional 51 [95% CI: 49 to 54] and mental health 48 [95% CI: 46 to 51]).

268

269 Two studies reported health-related QoL in individuals with PFP measured with EQ-5D,^{36,41}
270 but were unable to be pooled as they used different versions of the EQ-5D and one study³⁶
271 reported median score rather than mean. Scores from these 2 studies were mean 0.75
272 [standard deviation (SD)=0.12]⁴¹ and median 0.72 [interquartile range 0.68-0.78].³⁶

273


274 *Health-related QoL in individuals with PFP compared to population norms*

275 Relative to previously reported mean SF-36 domain scores from a general population
276 sample,²⁹ individuals with PFP had worse health-related QoL (mean difference: physical
277 function=34, role physical=36, bodily pain=30, general health=24, vitality=6, social
278 function=20, role emotional=23 and mental health=14). Additionally, amateur and
279 professional athletes with PFP from a single study, also had worse health-related QoL when
280 compared to previously published SF-36 scores from an active general population sample
281 (Table 4).²³

282

283 *Health-related QoL in individuals with PFP compared to pain-free controls*

284 Compared to mean SF-36 domain scores in pain-free controls,⁵ individuals with PFP had
285 worse health-related QoL (mean difference: physical function=38, role physical=47, bodily
286 pain=43, general health=25, vitality=18, social function=30, role emotional=37 and mental
287 health=16) (Figure 3).



288 **FIGURE 3:** Health-related quality of life in individuals with patellofemoral pain.

289

290 Individuals with PFP also had worse health-related QoL based on SF-36 PCS and MCS when
 291 compared to data from pain-free controls⁵ (mean difference: PCS=41, MCS=32) (Table 1).

292 Only one study reported EQ-5D scores in individuals with PFP (median score: 0.72)
 293 compared to pain-free controls (median score: 1.00).³⁶


294

295 3.4 Effects of PFP Intervention on QoL

296 Knee-related QoL

297 Two RCTs reported conflicting evidence for the effect of intervention on KOOS-QoL.^{34,41} A
 298 lower-quality and high risk of bias study showed that the combined treatment of a knee brace
 299 and multi-modal physical therapy, compared to multi-modal physical therapy alone
 300 significantly improved knee-related QoL (SMD=0.45 [95% CI: 0.13 to 0.77]).³⁴ A higher-
 301 quality and unclear risk of bias study reported no statistically significant differences in knee-
 302 related QoL between individuals with PFP receiving physical-therapist supervised
 303 neuromuscular retraining and home exercise with an education session, and those receiving
 304 an education session alone (SMD=0.31 [95% CI: -0.05 to 0.67]) (Figure 4).⁴¹

305




306 **FIGURE 4: Effect of intervention on quality of life in controlled studies.**

307

308 Pooled data from three lower-quality repeated measures design studies^{6,48,51} provided limited
 309 evidence of moderate improvement in knee-related QoL post-intervention (interventions

310 consisted of brace, off-axis elliptical trainer and tape) compared to pre-intervention
 311 (SMD=0.54 [95% CI: 0.04 to 1.04], $I^2=41\%$, $p=0.03$) (Figure 5).

312



313 **FIGURE 5: Effect of intervention on quality of life in repeated measures studies.**

314

315 Health-related QoL

316 Two RCTs reported conflicting evidence of the effect of intervention on SF-36 scores.^{14,49} A
 317 higher-quality and low risk of bias study investigated the effect of multi-modal physical
 318 therapy compared to a placebo intervention and found no significant differences between the
 319 domain scores of the two groups (Tables 1 and 2).¹⁴ Another higher-quality but high risk of
 320 bias study investigated the effects of two multi-modal physical therapy treatments; one based
 321 on McConnell taping and selective vastus medialis obliquus exercise (VMO), and the other
 322 comprised of sling taping and quadriceps strengthening.⁴⁹ QoL outcomes were compared to a
 323 (no treatment) control group. Large improvements were observed following analysis of
 324 combined mean PCS scores following multi-modal physical therapy for all treated
 325 individuals (SMD=0.93 [95% CI: 0.41 to 1.46]) relative to the control group. There was no
 326 significant difference in PCS or MCS scores between intervention groups. Large PCS score

327 improvements were observed following analysis of each intervention group compared to no
328 intervention; McConnell taping plus VMO exercise group (SMD=0.84 [95% CI: 0.23 to
329 1.44]) and the sling taping plus quadriceps strengthening group (SMD=0.87 [95% CI: 0.26 to
330 1.48]) (Figure 4).⁴⁹

331

332 Four repeated measures design studies reported health-related QoL pre- and post-
333 intervention.^{2,16,20,27} Pooled SF-36 summary scores from three lower-quality studies^{2,16,20}
334 provided limited evidence of large improvements in health-related QoL (PCS SMD=1.36
335 [95% CI: 0.19 to 2.54], $I^2=92%$, $p=0.02$, MCS SMD=0.46 [95% CI: 0.06 to 0.85], $I^2=46%$,
336 $p=0.02$) post-intervention (strengthening, biomechanical foot-worn device) relative to pre-
337 intervention (Figure 5). A lower-quality study investigated two intervention for PFP: (i)
338 Kinesio taping plus exercise program, and (ii) electrical stimulation of VMO plus exercise
339 program.²⁷ Compared to pre-intervention, both interventions resulted in significant
340 improvements in SF-36 domain scores, except for vitality.²⁷

341

342 **3.5 Factors associated with QoL in Individuals with PFP**

343 Due to the very limited number of controlled studies, random effects meta-analysis to
344 determine factors related to QoL outcomes in individuals with PFP could not be performed.

345

346 **4.0 DISCUSSION**

347 **4.1 QoL in Individuals with PFP**

348 This systematic review revealed that individuals with PFP had substantially worse knee- and
349 health-related QoL relative to pain-free controls (KOOS-QoL mean difference: 51, SF-36
350 domains mean difference range: 16-47) and population norms (KOOS-QoL mean difference:
351 37, SF-36 domains mean difference range: 14-36). Impairments in knee- and health-related

352 QoL, were highlighted by the fact that pooled PFP mean 95% CI upper limits were all lower
353 than the 95% CI lower limits for pain-free and normative QoL group means. Impairments in
354 SF-36 PCS scores in individuals with PFP compared to the reference group, were greater than
355 MCS scores, suggesting an emphasis on addressing physical impairments is needed to
356 improve QoL in individuals with PFP.

357

358 Recent systematic reviews indicate similar impairments in KOOS-QoL for a range of other
359 knee conditions, including knee osteoarthritis (pooled mean=35)¹³, anterior cruciate ligament
360 (ACL) injury (pooled mean=44)¹³, and 5-16 years following ACL reconstruction (pooled
361 mean=74)¹⁷. Our findings indicate that the impact of PFP (pooled mean=47) on knee-related
362 QoL approaches that of knee osteoarthritis. Additionally, knee-related QoL impairment in
363 people with PFP is similar or greater than QoL impairment following ACL injury, which is
364 considered to be a life-changing event with substantial physical and psychological
365 impacts.^{25,43}

366

367 Our findings indicate athletic cohorts with PFP (e.g. KOOS-QoL = 78)^{12,47} have better
368 knee- and health-related QoL compared to pooled findings of PFP cohorts without inclusion
369 based on athletic status (e.g. KOOS-QoL = 47). This finding is not surprising considering
370 athletes generally have an increased perception of their health in comparison with age-
371 matched peers.^{9,23,47} However, when compared to QoL norms measured in active populations,
372 our findings indicate both knee- and health-related QoL was impaired in athletes with PFP.

373

374 **4.2 Effects of PFP Intervention on QoL**

375 Findings from repeated measure intervention studies indicate that knee- and health-related
376 QoL improved following interventions for PFP including bracing, taping and exercise

377 therapy. Importantly, these improvements are greater than the minimal clinically important
378 improvement (MCII) reported for KOOS-QoL (8-10 points)⁴⁴ and the SF-36 PCS and MCS
379 (5-7 points).^{60,61} However, less improvement was observed in SF-36 MCS scores (mean
380 difference improvement: 6 points), perhaps reflecting the greater impairment in PCS
381 compared with MCS at baseline. Significant improvements in knee- and health- related QoL
382 following intervention in these repeated measure studies should be interpreted with caution.
383 Importantly, a lack of control or comparison group means it is unclear if these improvements
384 were the result of the intervention, placebo, physical-therapist interaction, natural history, or a
385 combination of these factors.⁵³ Unfortunately, there are currently very few RCTs to provide
386 further insight.

387

388 Very limited evidence from one RCT, indicated that despite significant improvements in pain
389 and function, knee-related QoL did not improve more following physical-therapy
390 intervention (i.e., patellofemoral soft tissue mobilisation, strength exercises, neuromuscular
391 training) plus education in comparison to education alone. It is possible that the KOOS-QoL
392 subscale (assessing lifestyle modification, knee awareness, knee confidence and knee
393 difficulties) may not be sensitive to changes in knee pain and function. Similarly, two RCTs
394 reported significant improvements in pain and function for individuals that received multi-
395 modal physical therapy compared to controls, but the impact of intervention on health-related
396 QoL was conflicting. Physical interventions may need to be specifically developed in order to
397 target improvements in knee- and health-related QoL. Further research is needed to determine
398 the most effective interventions for improving QoL in individuals with PFP.

399

400 Interestingly, Rathleff et al 2014, was the only RCT to encourage ongoing self management
401 and exercise in the longer term (i.e. 12 months) and was also the only controlled study

402 without a high risk of bias to report significant improvements in knee-related QoL at longer-
403 term follow up (i.e. 12 months), specifically in adolescents. This may indicate that improving
404 QoL in individuals with PFP requires longer-term physical interventions and follow up (e.g.
405 beyond the common 6-12 week clinical trial period), although further research is needed to
406 confirm this, particularly in adults.

407

408 **4.3 Limitations and Recommendations for Future Research**

409 Firstly, all relevant studies were included regardless of methodological quality due to the
410 paucity of research in this area. Therefore, low-quality studies may bias the findings. To
411 account for this, the levels of evidence reported in this review involve consideration of study
412 homogeneity, quality and quantity.

413

414 Previously published normative QoL data from Norway²⁹ and Sweden³³ were used for
415 comparison as these were the largest published normative samples. However the comparison
416 between Scandinavian normative QoL data and pooled QoL data from individuals with PFP
417 from many different countries, may have biased these results.¹ Although chronic
418 musculoskeletal conditions have been shown to have a similar impact on health-related QoL
419 measured by the SF-36 in eight (Western) countries³, comparison with non-Western cultures
420 is complex⁵² and such analysis is beyond the scope of this review.

421

422 Pain-free control group QoL data was very limited (i.e., 4 studies) which may bias pooled
423 mean knee- and health-related QoL comparisons against individuals with PFP. Additionally,
424 three of the four control groups were comprised of adolescent and adult women and lower
425 health-related QoL scores have been reported in women compared to men.^{10,26} However, due
426 to the small number of included studies reporting QoL data for men and women, sex-based

427 analyses were not conducted. Given sex-based differences associated with PFP, future
428 research should consider reporting data for men and women separately.

429

430 Most intervention studies included in this systematic review measured knee- or health-related
431 QoL as a secondary outcome, and hence may be underpowered to detect changes in QoL.⁵⁹
432 Considering we found markedly impaired QoL in individuals with PFP, future research
433 should consider QoL measures as a primary intervention target and power participant
434 recruitment accordingly. We were unable to determine whether other participant or
435 methodological factors are associated with QoL in individuals with PFP, due to the small
436 number of controlled studies published.

437

438 **5.0 CONCLUSION**

439 Individuals with PFP aged under 50 years, have impaired knee- and health-related QoL
440 compared to the general population and pain-free individuals. Based on current evidence,
441 including a paucity of high quality randomised controlled trials, it is unclear whether
442 common interventions provided to individuals with PFP have any beneficial effect on knee-
443 and health-related QoL when compared to a control group. Developing treatments to target
444 knee-related and health-related QoL in individuals with PFP and evaluating their efficacy in
445 longer-term, high-quality randomized controlled trials is urgently needed.

446

447

448

449

450

451

452

453

454

455 **REFERENCES:**

- 456 1. Aaronson N, Acquadro C, Alonso J, et al. International quality of life assessment (IQOLA)
457 project. *Quality of life research*. 1992;1(5):349-351.
- 458 2. Akkurt E, Salli A, Ozerbil OM, Ugurlu H. The effect of isokinetic exercise on symptoms,
459 functional status and EMG activation onset time of the vastus medialis oblique and vastus
460 lateralis in female patients with patellofemoral pain syndrome. *Isokinetics & Exercise
461 Science*. 2010;18(3):157-161.
- 462 3. Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic
463 conditions in eight countries: Results from the International Quality of Life Assessment
464 (IQOLA) Project. *Quality of Life Research*. 2004;13(2):283-298.
- 465 4. Apivatgaroon A, Anghong C, Sanguanjit P, Chernchujit B. The validity and reliability of the
466 Thai version of the Kujala score for patients with patellofemoral pain syndrome. *Disability
467 and rehabilitation*. 2016;38(21):2161-2164.
- 468 5. Assa T, Elbaz A, Mor A, et al. Gait metric profile of 157 patients suffering from anterior knee
469 pain. A controlled study. *The Knee*. 2013;20(1):40-44.
- 470 6. Banan M, Talebi G, M TD. A study on the effects of patellar taping on pain, quality of life and
471 radiographic findings in patients with patellofemoral pain syndrome. 2016.
- 472 7. Blond L, Hansen L. Patellofemoral pain syndrome in athletes: a 5.7-year retrospective follow-
473 up study of 250 athletes. *Acta Orthop Belg*. 1998;64(4):393-400.
- 474 8. Borenstein M. *Introduction to meta-analysis*. Oxford: Oxford : Wiley; 2009.
- 475 9. Cameron KL, Thompson BS, Peck KY, Owens BD, Marshall SW, Svoboda SJ. Normative values
476 for the KOOS and WOMAC in a young athletic population: history of knee ligament injury is
477 associated with lower scores. *The American journal of sports medicine*. 2013;41(3):582-589.
- 478 10. Cherepanov D, Palta M, Fryback DG, Robert SA. Gender differences in health-related quality-
479 of-life are partly explained by sociodemographic and socioeconomic variation between adult
480 men and women in the US: evidence from four US nationally representative data sets.
481 *Quality of life research*. 2010;19(8):1115-1124.
- 482 11. Cheung RTh, Ngai SPc, Lam PL, Chiu JKw, Fung EYh. Chinese translation and validation of the
483 Kujala scale for patients with patellofemoral pain. *Disability & Rehabilitation*.
484 2012;34(6):510-513.
- 485 12. Cheung RTH, Zhang Z, Ngai SPC. Different Relationships Between the Level of Patellofemoral
486 Pain and Quality of Life in Professional and Amateur Athletes. *PM&R*. 2013;5(7):568-572.
- 487 13. Collins NJ, Prinsen CAC, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and
488 Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement
489 properties. *Osteoarthritis and Cartilage*. 2016;24(8):1317-1329.
- 490 14. Crossley K, Bennell K, Green S, Cowan S, McConnell J. Physical Therapy for Patellofemoral
491 Pain: A Randomized, Double-Blinded, Placebo-Controlled Trial. *The American Journal of
492 Sports Medicine*. 2002;30(6):857-865.
- 493 15. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the
494 methodological quality both of randomised and non-randomised studies of health care
495 interventions. *Journal of Epidemiology and Community Health*. 1998;52(6):377-384.
- 496 16. Eapen C, Nayak CD, Pazhyaottyil Zulfeequer C. Effect of Eccentric Isotonic Quadriceps Muscle
497 Exercises on Patellofemoral Pain Syndrome: An Exploratory Pilot Study. *Asian Journal of
498 Sports Medicine*. 2011;2(4):227-234.

- 499 17. Filbay SR, Ackerman IN, Russell TG, Macri EM, Crossley KM. Health-Related Quality of Life
500 After Anterior Cruciate Ligament Reconstruction: A Systematic Review. *The American Journal*
501 *of Sports Medicine*. 2014;42(5):1247-1255.
- 502 18. Gail M. Sullivan, Richard Feinn. Using Effect Size—or Why the P Value Is Not Enough. *Journal*
503 *of Graduate Medical Education*. 2012;4(3):279-282.
- 504 19. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Annals of internal*
505 *medicine*. 1993;118(8):622-629.
- 506 20. Haim A, Segal G, Elbaz A, et al. The outcome of a novel biomechanical therapy for patients
507 suffering from anterior knee pain. *The Knee*. 2013;20(6):595-599.
- 508 21. Hart HF, Stefanik JJ, Wyndow N, Machotka Z, Crossley KM. The prevalence of radiographic
509 and MRI-defined patellofemoral osteoarthritis and structural pathology: a systematic review
510 and meta-analysis. *Br J Sports Med*. 2017:bjsports-2017-097515.
- 511 22. Higgins JPT, Altman DG, et al. The Cochrane Collaboration's tool for assessing risk of bias
512 in randomised trials. *BMJ: British Medical Journal*. 2011;343(7829):889-893.
- 513 23. Huffman GR, Park J, Roser-Jones C, Sennett BJ, Yagnik G, Webner D. Normative SF-36 values
514 in competing NCAA intercollegiate athletes differ from values in the general population. *The*
515 *Journal of Bone & Joint Surgery*. 2008;90(3):471-476.
- 516 24. Iversen MD, Price LL, von Heideken J, Harvey WF, Wang C. Physical examination findings and
517 their relationship with performance-based function in adults with knee osteoarthritis. *BMC*
518 *musculoskeletal disorders*. 2016;17(1):273.
- 519 25. Janssen K, Orchard J, Driscoll T, Van Mechelen W. High incidence and costs for anterior
520 cruciate ligament reconstructions performed in Australia from 2003–2004 to 2007–2008:
521 time for an anterior cruciate ligament register by Scandinavian model? *Scandinavian journal*
522 *of medicine & science in sports*. 2012;22(4):495-501.
- 523 26. Jörngården A, Wettergen L, von Essen L. Measuring health-related quality of life in
524 adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the
525 influence of age, gender, and method of administration. *Health and quality of life outcomes*.
526 2006;4(1):91.
- 527 27. Kuru T, Yalman A, Dereli EE. Comparison of efficiency of Kinesio® taping and electrical
528 stimulation in patients with patellofemoral pain syndrome. *Acta orthopaedica et*
529 *traumatologica turcica*. 2011;46(5):385-392.
- 530 28. Lankhorst N, van Middelkoop M, Crossley K, et al. Factors that predict a poor outcome 5–8
531 years after the diagnosis of patellofemoral pain: a multicentre observational analysis. *Br J*
532 *Sports Med*. 2015:bjsports-2015-094664.
- 533 29. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general
534 Norwegian population. *Scandinavian Journal of Public Health*. 1998;26(4):250-258.
- 535 30. Moher D, Liberati A, Tetzlaff J, Altman DG, and the PG. Preferred reporting items for
536 systematic reviews and meta-analyses: The prisma statement. *Annals of Internal Medicine*.
537 2009;151(4):264-269.
- 538 31. Mølgaard C, Rathleff MS, Simonsen O. Patellofemoral Pain Syndrome and Its Association
539 with Hip, Ankle, and Foot Function in 16- to 18-Year-Old High School Students. *Journal of the*
540 *American Podiatric Medical Association*. 2011;101(3):215-222.
- 541 32. Negahban H, Pouretzad M, Sohani SM, Mazaheri M, Salavati M, Mohammadi F. Validation
542 of the Persian version of Functional Index Questionnaire (FIQ) and Modified FIQ in patients
543 with patellofemoral pain syndrome. *Physiotherapy theory and practice*. 2013;29(7):521-530.
- 544 33. Paradowski PT, Bergman S, Sundén-Lundius A, Lohmander LS, Roos EM. Knee complaints
545 vary with age and gender in the adult population. Population-based reference data for the
546 Knee injury and Osteoarthritis Outcome Score (KOOS). *BMC musculoskeletal disorders*.
547 2006;7(1):38.

- 548 34. Petersen W, Ellermann A, Rembitzki IV, et al. Evaluating the potential synergistic benefit of a
549 realignment brace on patients receiving exercise therapy for patellofemoral pain syndrome:
550 a randomized clinical trial. *Archives of orthopaedic and trauma surgery*. 2016:1-8.
- 551 35. Powers CM. The influence of altered lower-extremity kinematics on patellofemoral joint
552 dysfunction: a theoretical perspective. *Journal of Orthopaedic & Sports Physical Therapy*.
553 2003;33(11):639-646.
- 554 36. Rathleff CR, Baird WN, Olesen JL, Roos EM, Rasmussen S, Rathleff MS. Hip and Knee Strength
555 Is Not Affected in 12-16 Year Old Adolescents with Patellofemoral Pain - A Cross-Sectional
556 Population-Based Study. *PLoS ONE*. 2013;8(11):e79153.
- 557 37. Rathleff CR, Olesen JL, Roos EM, Rasmussen S, Rathleff MS. Half of 12-15-year-olds with
558 knee pain still have pain after one year. *Dan Med J*. 2013;60(11):A4725.
- 559 38. Rathleff M, Rathleff C, Crossley K, Barton C. Is hip strength a risk factor for patellofemoral
560 pain? A systematic review and meta-analysis. *British journal of sports medicine*.
561 2014:bjsports-2013-093305.
- 562 39. Rathleff MS, Petersen KK, Arendt-Nielsen L, Thorborg K, Graven-Nielsen T. Impaired
563 conditioned pain modulation in young female adults with long-standing patellofemoral pain:
564 a single blinded cross-sectional study. *Pain Medicine*. 2016:pnv017.
- 565 40. Rathleff MS, Rathleff CR, Olesen JL, Rasmussen S, Roos EM. Is Knee Pain During Adolescence
566 a Self-limiting Condition? *The American Journal of Sports Medicine*. 2016;44(5):1165-1171.
- 567 41. Rathleff MS, Roos EM, Olesen JL, Rasmussen S. Exercise during school hours when added to
568 patient education improves outcome for 2 years in adolescent patellofemoral pain: a cluster
569 randomised trial. *British Journal of Sports Medicine*. 2014;49(6):406-412.
- 570 42. Rathleff MS, Samani A, Olesen JL, et al. Neuromuscular activity and knee kinematics in
571 adolescents with patellofemoral pain. *Medicine and science in sports and exercise*.
572 2013;45(9):1730-1739.
- 573 43. Risberg MA, Grindem H, Øiestad BE. We Need to Implement Current Evidence in Early
574 Rehabilitation Programs to Improve Long-Term Outcome After Anterior Cruciate Ligament
575 Injury. *Journal of Orthopaedic & Sports Physical Therapy*. 2016;46(9):710-713.
- 576 44. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from
577 joint injury to osteoarthritis. *Health and quality of life outcomes*. 2003;1(1):64.
- 578 45. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynon BD. Knee Injury and Osteoarthritis
579 Outcome Score (KOOS)—Development of a Self-Administered Outcome Measure. *Journal of*
580 *Orthopaedic & Sports Physical Therapy*. 1998;28(2):88-96.
- 581 46. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in
582 randomised controlled trials: bibliographic study. *Bmj*. 1998;317(7167):1191-1194.
- 583 47. Silva DdO, Coura MB, Waiteman M, et al. Patellofemoral pain and sports practice: reduced
584 symptoms and higher quality of life in adolescent athletes as compared to non-athletes.
585 *Motriz: Revista de Educação Física*. 2016;22:84-89.
- 586 48. Sinclair JK, Selfe J, Taylor PJ, Shore HF, Richards JD. Influence of a knee brace intervention on
587 perceived pain and patellofemoral loading in recreational athletes. *Clinical Biomechanics*.
588 2016;37:7-12.
- 589 49. Syme G, Rowe P, Martin D, Daly G. Disability in patients with chronic patellofemoral pain
590 syndrome: A randomised controlled trial of VMO selective training versus general
591 quadriceps strengthening. *Manual Therapy*. 2009;14(3):252-263.
- 592 50. Tornbjerg SM, Nissen N, Englund M, et al. Structural pathology is not related to patient-
593 reported pain and function in patients undergoing meniscal surgery. *Br J Sports Med*.
594 2016:bjsports-2016-096456.
- 595 51. Tsai L-C, Lee SJ, Yang AJ, Ren Y, Press JM, Zhang L-Q. Effects of off-axis elliptical training on
596 reducing pain and improving knee function in individuals with patellofemoral pain. *Clinical*
597 *journal of sport medicine: official journal of the Canadian Academy of Sport Medicine*.
598 2015;25(6):487.

- 599 52. Tseng H-M, Lu J-fR, Gandek B. Cultural Issues in Using the SF-36 Health Survey in Asia:
600 Results from Taiwan. *Health and Quality of Life Outcomes*. 2003;1(1):72.
- 601 53. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects
602 in pain treatment and research. *JAMA*. 1994;271(20):1609-1614.
- 603 54. van der Heijden RA, Lankhorst NE, van Linschoten R, Bierma-Zeinstra S, van Middelkoop M.
604 Exercise for treating patellofemoral pain syndrome. *The Cochrane Library*. 2015(1).
- 605 55. Van Middelkoop M, Van Linschoten R, Berger MY, Koes BW, Bierma-Zeinstra SM. Knee
606 complaints seen in general practice: active sport participants versus non-sport participants.
607 *BMC musculoskeletal disorders*. 2008;9(1):36.
- 608 56. Van Tulder M, Furlan A, Bombardier C, Bouter L, Group EBotCCBR. Updated method
609 guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. *Spine*.
610 2003;28(12):1290-1299.
- 611 57. Vincent HK, Lamb KM, Day TI, Tillman SM, Vincent KR, George SZ. Morbid obesity is
612 associated with fear of movement and lower quality of life in patients with knee pain-related
613 diagnoses. *PM&R*. 2010;2(8):713-722.
- 614 58. Viswanathan M, Patnode CD, Berkman ND, et al. Recommendations for assessing the risk of
615 bias in systematic reviews of health-care interventions. *Journal of Clinical Epidemiology*.
616 2018;97:26-34.
- 617 59. Waal JMvd, Terwee CB, Windt DAvd, Bouter LM, Dekker J. The impact of non-traumatic hip
618 and knee disorders on health-related quality of life as measured with the SF-36 or SF-12. A
619 systematic review. *Quality of Life Research*. 2005;14(4):1141-1155.
- 620 60. Ward MM, Guthrie LC, Alba MI. Clinically Important Changes in Short Form 36 Health Survey
621 Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness.
622 *Arthritis Care Res (Hoboken)*. 2014;66(12):1783-1789.
- 623 61. Ware JE, Kosinski M, Dewey JE, Gandek B. *SF-36 health survey: manual and interpretation*
624 *guide*. Quality Metric Inc.; 2000.
- 625 62. Wood L, Muller S, Peat G. The epidemiology of patellofemoral disorders in adulthood: a
626 review of routine general practice morbidity recording. *Primary Health Care Research &*
627 *Development*. 2011;12(2):157-164.

628

629

APPENDIX 1: Search Strategy for MEDLINE

CONCEPT	KEYWORDS	MESH HEADING	
Patellofemoral pain	1. anterior knee pain.mp. 2. patella* or femoropatell* or retropatell* or patellofemoral or patello-femoral <i>adj2</i> pain or syndrome or dysfunction.mp 3. lateral compression or lateral facet or lateral pressure or odd facet <i>adj2</i> syndrome.mp 4. chondromalac* or chondropath* or chondrosis <i>adj2</i> patell* or femoropatell* or retropatell* or femoro-patell*.mp.	5. Patella/ or Knee joint/ or Knee/ AND Pain/ or Arthralgia/ 6. Patellofemoral pain syndrome/ 7. Chondromalacia Patellae/	8. OR/1-7
Quality of life	9. Knee Injury and Osteoarthritis Outcome Score or KOOS.mp. 10. Short?form 36 OR SF?36 OR Short?form 12 OR SF?12 OR Short Form Health Survey.mp. 11. EQ5D OR EQ-5D*.mp. 12. QOL OR AQOL OR Health related quality of life or HRQOL.mp. 13. lower extremity activity profile or leap.mp	14. Quality of life/	15. OR/9-14
			16. 8. AND 15.

APPENDIX 2. *Modified Downs & Black checklist for methodological quality appraisal.*

Item	Title	Description by Downs& Black	Yes	No/Unable to determine	Partially	Inter-vention	Cross-section	Validity
1	Aim	Is the hypothesis/aim/objective clearly described?	1	0				
2	Outcomes	Are the main outcomes to be measured clearly described in the Introduction or Methods section?	1	0				
3	Participants	Are the characteristics of the patients included in the study clearly described?	1	0				
5	Confounders	Are distributions of principal confounders in each group of subjects to be compared clearly described?	2	0	1			N/A
6	Findings	Are the main findings of the study clearly described?	1	0				
7	Random variability	Does the study provide estimates of the random variability in the data for the main outcomes	1	0				
10	Probability	Have actual probability values been reported for the main outcomes except where the probability value is less than 0.001?	1	0				N/A
11	External validity	Were the subjects asked to participate in the study representative of the entire population from which they were recruited?	1	0				
12	External validity	Were those subjects who were prepared to participate representative of the entire population from which they were recruited?	1	0				
15	Blinding	Was an attempt made to blind those measuring the main outcomes of the intervention?	1	0				N/A
18	Statistical tests	Were the statistical tests used to assess the main outcomes appropriate?	1	0				N/A
20	Accurate outcomes	Were the main outcome measures used accurate (valid and reliable)?	1	0				
25	Confounding adjustment	Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?	1	0				N/A
26	Loss to follow-up	Were losses of patients to follow-up taken into account?	1	0			N/A	N/A
27	Power	Did the study have sufficient power to detect a clinically important effect where probability value for difference being due to chance is < 5%	1	0				N/A
	Max score		16			16	15	8

Note. N/A is not applicable

HIGHLIGHTS

People with patellofemoral pain have impaired quality of life

Quality of life is worse than the general population

Quality of life is worse than pain-free people

Physical therapy may improve quality of life

ACCEPTED MANUSCRIPT